First human tests begin for new RSV shot using mRNA technology
NCT ID NCT07418229
Summary
This is an early safety study for a new vaccine designed to protect against Respiratory Syncytial Virus (RSV). The trial will enroll 60 healthy adults to test different doses of a freeze-dried mRNA vaccine. Researchers will closely monitor participants for any side effects after vaccination to determine if the vaccine is safe for further testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qinxian Center for Disease Control and Prevention
Changzhi, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.